SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- University Hospital of Würzburg
- Institute of Social Pediatrics and Adolescent Medicine
- Ruhr University Bochum
- University of Münster
- Klinikum Oldenburg
- University of Bonn
- University Medical Center Göttingen
- Heidelberg University
Abstract
PURPOSE: The study evaluates the effects on sero-immunity, health status and quality of life of children and adolescents after the upsurge of the Omicron variant in Germany.
METHODS: This multicenter cross-sectional study (IMMUNEBRIDGE Kids) was conducted within the German Network University Medicine (NUM) from July to October 2022. SARS-CoV-2- antibodies were measured and data on SARS-CoV-2 infections, vaccinations, health and socioeconomic factors as well as caregiver-reported evaluation on their children's health and psychological status were assessed.
RESULTS: 497 children aged 2-17 years were included. Three groups were analyzed: 183 pre-schoolchildren aged 2-4 years, 176 schoolchildren aged 5-11 years and 138 adolescents aged 12-18 years. Positive antibodies against the S- or N-antigen of SARS-CoV-2 were detected in 86.5% of all participants (70.0% [128/183] of pre-schoolchildren, 94.3% of schoolchildren [166/176] and 98.6% of adolescents [136/138]). Among all children, 40.4% (201/497) were vaccinated against COVID-19 (pre-schoolchildren 4.4% [8/183], schoolchildren 44.3% [78/176] and adolescents 83.3% [115/138]). SARS-CoV-2 seroprevalence was lowest in pre-school. Health status and quality of life reported by the parents were very positive at the time of the survey (Summer 2022).
CONCLUSION: Age-related differences on SARS-CoV-2 sero-immunity could mainly be explained by differences in vaccination rates based on the official German vaccination recommendations as well as differences in SARS-CoV-2 infection rates in the different age groups. Health status and quality of life of almost all children were very good independent of SARS-CoV-2 infection and/or vaccination.
TRIAL REGISTRATION: German Registry for Clinical Trials Identifier Würzburg: DRKS00025546 (registration: 11.09.2021), Bochum: DRKS00022434 (registration:07.08.2020), Dresden: DRKS 00022455 (registration: 23.07.2020).
Details
Original language | English |
---|---|
Pages (from-to) | 1531-1539 |
Number of pages | 9 |
Journal | Infection |
Volume | 51 |
Issue number | 5 |
Publication status | E-pub ahead of print - 6 Jun 2023 |
Peer-reviewed | Yes |
External IDs
PubMedCentral | PMC10243264 |
---|---|
Scopus | 85161341288 |
Keywords
Sustainable Development Goals
Keywords
- Adolescent, Child, Humans, Child, Preschool, Quality of Life, SARS-CoV-2, Cross-Sectional Studies, COVID-19/epidemiology, Seroepidemiologic Studies, Antibodies, Viral, Vaccination